This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy | MicrobiomeTrials
← Back to trials NCT07023614
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-10-06Est. Completion: 2026-12
Enrollment target: 165 participantsLocations Imbria Investigational Site, La Jolla, California, United States Imbria Investigational Site, Los Angeles, California, United States Imbria Investigational Site, San Francisco, California, United States Imbria Investigational Site, Washington D.C., District of Columbia, United States Imbria Investigational Site, Miami, Florida, United States Imbria Investigational Site, Atlanta, Georgia, United States Imbria Investigational Site, Chicago, Illinois, United States Imbria Investigational Site, Oak Lawn, Illinois, United States Imbria Investigational Site, Baltimore, Maryland, United States Imbria Investigational Site, Boston, Massachusetts, United States Imbria Investigational Site, Burlington, Massachusetts, United States Imbria Investigational Site, Grand Rapids, Michigan, United States Imbria Investigational Site, Rochester, Minnesota, United States Imbria Investigational Site, St Louis, Missouri, United States Imbria Investigational Site, New York, New York, United States Imbria Investigational Site, New York, New York, United States Other microbiome trials you might be interested in Obstructive Hypertrophic Cardiomyopathy
Researchers are looking for a better way to treat Japanese people who have symptomatic obstructive hypertrophic cardiomy…
Kurume, Japan Est. completion Jul 14, 2026
Nonobstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses o…
Boston, United States Est. completion Mar 2027
Imbria Investigational Site, Charlotte, North Carolina, United States
Imbria Investigational Site, Portland, Oregon, United States
Imbria Investigational Site, Philadelphia, Pennsylvania, United States
Imbria Investigational Site, Philadelphia, Pennsylvania, United States
Imbria Investigational Site, Houston, Texas, United States
Imbria Investigational Site, Houston, Texas, United States
Imbria Investigational Site, Plano, Texas, United States
Imbria Investigational Site, Salt Lake City, Utah, United States
Imbria Investigational Site, Charlottesville, Virginia, United States
Imbria Investigational Site, Richmond, Virginia, United States
Imbria Investigational Site, Milwaukee, Wisconsin, United States
Imbria Investigational Site, Graz, Austria
Imbria Investigational Site, Edegem, Belgium
Imbria Investigational Site, Montpellier, France
Imbria Investigational Site, Paris, France
Imbria Investigational Site, Saint-Herblain, France
Imbria Investigational Site, Bad Oeynhausen, Germany
Imbria Investigational Site, Göttingen, Germany
Imbria Investigational Site, Heidelberg, Germany
Imbria Investigational Site, Jena, Germany
Imbria Investigational Site, Bologna, Italy
Imbria Investigational Site, Florence, Italy
Imbria Investigational Site, Massa, Italy
Imbria Investigational Site, Milan, Italy
Imbria Investigational Site, Milan, Italy
Imbria Investigational Site, Milan, Italy
Imbria Investigational Site, Naples, Italy
Imbria Investigational Site, Amsterdam-Zuidoost, Netherlands
Imbria Investigational Site, Leiden, Netherlands
Imbria Investigational Site, Nijmegen, Netherlands
Imbria Investigational Site, Rotterdam, Netherlands
Imbria Investigational Site, Katowice, Poland
Imbria Investigational Site, Warsaw, Poland
Imbria Investigational Site, Wroclaw, Poland
Imbria Investigational Site, Guimarães, Portugal
Imbria Investigational Site, Lisbon, Portugal
Imbria Investigational Site, Lisbon, Portugal
Imbria Investigational Site, Lisbon, Portugal
Imbria Investigational Site, Barcelona, Barcelona, Spain
Imbria Investigational Site, A Coruña, Galicia, Spain
Imbria Investigational Site, Madrid, Madrid, Spain
Imbria Investigational Site, Vigo, Pontevedra, Spain
Imbria Investigational Site, Seville, Sevilla, Spain
Imbria Investigational Site, Seville, Sevilla, Spain
Imbria Investigational Site, Barcelona, Spain
Imbria Investigational Site, Barcelona, Spain
Imbria Investigational Site, Barcelona, Spain
Imbria Investigational Site, El Palmar, Spain
Imbria Investigational Site, Granada, Spain
Imbria Investigational Site, Madrid, Spain
Imbria Investigational Site, Madrid, Spain
Imbria Investigational Site, Palma de Mallorca, Spain
Imbria Investigational Site, Salamanca, Spain
Imbria Investigational Site, Valencia, Spain
Imbria Investigational Site, Valencia, Spain
Imbria Investigational Site, London, England, United Kingdom
Imbria Investigational Site, Glasgow, Scotland, United Kingdom
Imbria Investigational Site, London, United Kingdom
Imbria Investigational Site, London, United Kingdom
Imbria Investigational Site, Oxford, United Kingdom